Outcome and prognostic markers in severe drug-induced liver disease.
about
Drug-induced liver injury: a clinical updateDrug-induced liver injury: present and futureHepatotoxicity observed in clinical trials of aplaviroc (GW873140)Acute liver failure including acetaminophen overdoseHepatotoxicity by Drugs: The Most Common Implicated AgentsCauses, clinical features and outcomes of drug-induced liver injury in hospitalized patients in a Chinese tertiary care hospitalDrug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment OptionsSpectrum of Eosinophilic End-Organ ManifestationsIdiosyncratic adverse drug reactions: current conceptsBenefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetesAtypical causes of cholestasisRecent advances in management of acute liver failureCausality assessment in hepatotoxicity by drugs and dietary supplementsBiomarkers in DILI: One More Step ForwardA fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: Case reportHLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicityMulticenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumoniaHigh Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD CohortDrug-induced liver injury: recent advances in diagnosis and risk assessment.Hepatotoxicity of targeted therapy for cancer.Systematic Review and Meta-Analysis: Macrolides- and Amoxicillin/Clavulanate-induced Acute Liver Injury.Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data.A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data.Associations of gender and age with the reporting of drug-induced hepatic failure: data from the VigiBase™.Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database.Death and Liver Transplantation within Two Years of Onset of Drug-Induced Liver Injury.Penicillinase-resistant antibiotics induce non-immune-mediated cholestasis through HSP27 activation associated with PKC/P38 and PI3K/AKT signaling pathwaysSAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver diseaseAzathioprine and 6-Mercaptopurine-induced Liver Injury: Clinical Features and OutcomesStatin therapy and hepatotoxicity: Appraisal of the safety profile of atorvastatin in hyperlipidemic patients.Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed DatabaseIdiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset.Two-year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study.Mining hidden knowledge for drug safety assessment: topic modeling of LiverTox as a case study.Hepatic safety of antibiotics used in primary careRisk factors for idiosyncratic drug-induced liver injury.An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters.Value of preapproval safety data in predicting postapproval hepatic safety and assessing the legitimacy of class warning.Prevalence and incidence of liver dysfunction and assessment of biomarkers of liver disease in HIV-infected Asian children.
P2860
Q24617074-682FC1B5-C19D-494C-9CFB-F778BD8EDBA7Q24630227-B5A5C35B-ADE8-4C4A-B0D1-D83BD6B3079EQ24641929-CB134079-9C81-41EB-A44E-2945DB7E2523Q24647134-475D6F15-7D7F-49D3-A91B-EE84C0DB5516Q26767251-2BFBB6B1-5BBD-4483-B8C8-FDA1B6E1C77EQ26772063-1289FB7F-6255-4AA8-B421-705FD3F8E10FQ26781892-3578D90F-420A-4AC0-A3E3-214483BBC0BCQ26799618-A94ED25D-82C6-4EB7-950C-255AC07CEFFCQ26824391-6895DEBC-4AD8-4803-95C3-B1E6D2AD3C0FQ26853571-9FEEA03C-0B19-4FDF-82B1-AB9AA97184EFQ27013650-F4C019C9-10DB-4501-9812-3A220A6A8129Q27028034-854739AE-E33E-4595-AFDF-A695B5D7B91AQ27488354-3F82E604-063D-4A04-90FE-3888A72750F4Q28071799-120AE1E4-0937-40DE-A427-4B66819F9FF7Q28221763-5360068E-F91A-4E43-ACDD-E4DC5C00A895Q28534593-C5A9B1FE-81E0-49C3-BA66-CD89D171475DQ28542714-919D1CD3-60A7-4D71-A4E3-E0D55C40761DQ28550768-E0441961-404C-410C-8535-769277AA68D0Q30235089-3EEAB74F-37DE-4E15-B390-38D37267567EQ30250288-1A3990F4-F607-433F-ACDA-6392F9272294Q30251991-E242596C-65ED-4674-A492-2512154B24C6Q30582650-46BA5DE5-63D1-4B4F-BCA6-BCB83045E54DQ30585177-01F52E6C-E6D2-495B-B0C7-A41D16555AFDQ30594318-5F86C6D8-D721-45BB-9CEB-5477BD845F0DQ30852962-5DF5617F-BAD1-474B-8DBA-6491660F7C9DQ33442111-FD25BE21-0915-416C-B146-E3F50217FF60Q33687525-3257C52F-A15C-46F1-98D5-568CDFA25F69Q33759095-2C8C5F74-B6C1-428C-95A4-668ED3ED029FQ33894632-E036D720-CAF3-464A-BEDD-38EC2A580D80Q34169932-236E9127-4EE5-4C45-ABBF-6E0D84F6B42BQ34588945-6C4DA071-517C-4F20-A87A-D9319A0F5788Q34784297-438CF37F-9353-4724-BB17-6A38A4892B11Q34848118-AAD9E04C-4957-4AFB-8E2D-DD5D3ADCBF7BQ34921780-2644A8CF-B945-43C3-BB24-262CB89F621EQ35005256-BE712B81-7C15-41E5-BCB9-0D3841CD009DQ35037383-C30EB7A9-0107-42B5-8E7B-46E7A14011C9Q35168108-95686384-4DE3-48B4-9E9B-775283D4DCFDQ35206374-30DB0EAC-395F-46CC-94A7-3041D7BD1FBAQ35216989-1FA500C1-9A79-4AB0-ACE6-7B5AFED2D4D3Q35619539-958AFAD5-6E07-41B1-896F-CAA3ABECDEF8
P2860
Outcome and prognostic markers in severe drug-induced liver disease.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Outcome and prognostic markers in severe drug-induced liver disease.
@ast
Outcome and prognostic markers in severe drug-induced liver disease.
@en
Outcome and prognostic markers in severe drug-induced liver disease.
@nl
type
label
Outcome and prognostic markers in severe drug-induced liver disease.
@ast
Outcome and prognostic markers in severe drug-induced liver disease.
@en
Outcome and prognostic markers in severe drug-induced liver disease.
@nl
prefLabel
Outcome and prognostic markers in severe drug-induced liver disease.
@ast
Outcome and prognostic markers in severe drug-induced liver disease.
@en
Outcome and prognostic markers in severe drug-induced liver disease.
@nl
P356
P1433
P1476
Outcome and prognostic markers in severe drug-induced liver disease.
@en
P2093
Einar Björnsson
Rolf Olsson
P2860
P304
P356
10.1002/HEP.20800
P407
P577
2005-08-01T00:00:00Z